Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab

Biochemistry

Volumn 52, Issue 26, 2013, Pages 4531-4540

  Wilken, Jason A ^a,e   Perez Torres, Marianela ^b   Nieves Alicea, Rene ^b,g   Cora, Elsa M ^b   Christensen, Trace A ^c   Baron, Andre T ^d,f   Maihle, Nita J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^e CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^f Tumor Biology Investment Group Inc   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENTS; CLINICAL TRIAL; EPIDERMAL GROWTH FACTOR RECEPTORS; HIGH AFFINITY; HUMAN TISSUES; METALLO-PROTEASE; PROTEOLYTIC CLEAVAGE; SERUM BIOMARKERS;

BODY FLUIDS; CELL MEMBRANES; MOLECULAR INTERACTIONS; MONOCLONAL ANTIBODIES;

GLYCOSYLATION;

4 AMINOPHENYLMERCURIC ACETATE; ALPHA5 INTEGRIN; BETA1 INTEGRIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; INTEGRIN; METALLOPROTEINASE; TRASTUZUMAB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL SURFACE; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHO CELLS; CLINICAL TRIALS AS TOPIC; CRICETINAE; EPIDERMAL GROWTH FACTOR; HUMANS; INTEGRINS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84880176002     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi400437d     Document Type: Article

References (59)

1. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19, 3159-3167
2. Lafky, J. M., Wilken, J. A., Baron, A. T., and Maihle, N. J. (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer Biochim. Biophys. Acta 1785, 232-265
3. Liu, P. C., Liu, X., Li, Y., Covington, M., Wynn, R., Huber, R., Hillman, M., Yang, G., Ellis, D., Marando, C., Katiyar, K., Bradley, J., Abremski, K., Stow, M., Rupar, M., Zhuo, J., Li, Y. L., Lin, Q., Burns, D., Xu, M., Zhang, C., Qian, D. Q., He, C., Sharief, V., Weng, L., Agrios, C., Shi, E., Metcalf, B., Newton, R., Friedman, S., Yao, W., Scherle, P., Hollis, G., and Burn, T. C. (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells Cancer Biol. Ther. 5, 657-664
4. Zabrecky, J. R., Lam, T., McKenzie, S. J., and Carney, W. (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3 J. Biol. Chem. 266, 1716-1720
5. Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., and Baselga, J. (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells Cancer Res. 59, 1196-1201
6. Pupa, S. M., Menard, S., Morelli, D., Pozzi, B., De Palo, G., and Colnaghi, M. I. (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage Oncogene 8, 2917-2923
7. Rio, C., Buxbaum, J. D., Peschon, J. J., and Corfas, G. (2000) Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4 J. Biol. Chem. 275, 10379-10387
8. Vecchi, M., Baulida, J., and Carpenter, G. (1996) Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation J. Biol. Chem. 271, 18989-18995
9. Sanderson, M. P., Keller, S., Alonso, A., Riedle, S., Dempsey, P. J., and Altevogt, P. (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion J. Cell Biochem. 103, 1783-1797
10. Perez-Torres, M., Valle, B. L., Maihle, N. J., Negron-Vega, L., Nieves-Alicea, R., and Cora, E. M. (2008) Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells Exp. Cell Res. 314, 2907-2918
11. Zhen, Y., Caprioli, R. M., and Staros, J. V. (2003) Characterization of glycosylation sites of the epidermal growth factor receptor Biochemistry 42, 5478-5492
12. Baron, A. T., Wilken, J. A., Haggstrom, D. E., Goodrich, S. T., and Maihle, N. J. (2009) Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer IDrugs 12, 302-308
13. Reiter, J. L., Threadgill, D. W., Eley, G. D., Strunk, K. E., Danielsen, A. J., Sinclair, C. S., Pearsall, R. S., Green, P. J., Yee, D., Lampland, A. L., Balasubramaniam, S., Crossley, T. D., Magnuson, T. R., James, C. D., and Maihle, N. J. (2001) Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms Genomics 71, 1-20
14. Reiter, J. L. and Maihle, N. J. (2003) Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta Ann. N.Y. Acad. Sci. 995, 39-47
15. Baron, A. T., Cora, E. M., Lafky, J. M., Boardman, C. H., Buenafe, M. C., Rademaker, A., Liu, D., Fishman, D. A., Podratz, K. C., and Maihle, N. J. (2003) Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer Cancer Epidemiol. Biomarkers Prev. 12, 103-113
16. Wilken, J. A., Baron, A. T., and Maihle, N. J. (2010) The epidermal growth factor receptor conundrum Cancer 117, 2358-2360
17. Christensen, T. A., Reiter, J. L., Baron, A. T., and Maihle, N. J. (2002) Generation and characterization of polyclonal antibodies specific for human p110 sEGFR Hybrid Hybridomics 21, 183-189
18. Baron, A. T., Huntley, B. K., Lafky, J. M., Reiter, J. L., Liebenow, J., McCormick, D. J., Ziesmer, S. C., Roche, P. C., and Maihle, N. J. (1997) Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain Hybridoma 16, 259-271
19. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature (London) 227, 680-685
20. Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C., Burgess, A. W., and Ward, C. W. (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha Cell 110, 763-773
21. Elleman, T. C., Domagala, T., McKern, N. M., Nerrie, M., Lonnqvist, B., Adams, T. E., Lewis, J., Lovrecz, G. O., Hoyne, P. A., Richards, K. M., Howlett, G. J., Rothacker, J., Jorissen, R. N., Lou, M., Garrett, T. P., Burgess, A. W., Nice, E. C., and Ward, C. W. (2001) Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain Biochemistry 40, 8930-8939
22. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., and Yokoyama, S. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110, 775-787
23. Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H. S., Leahy, D. J., and Lemmon, M. A. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization Mol. Cell 11, 507-517
24. Alvarado, D., Klein, D. E., and Lemmon, M. A. (2010) Structural basis for negative cooperativity in growth factor binding to an EGF receptor Cell 142, 568-579
25. Couet, J., Sar, S., Jolivet, A., Hai, M. T., Milgrom, E., and Misrahi, M. (1996) Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease J. Biol. Chem. 271, 4545-4552
26. Guan, R., Zhang, Y., Jiang, J., Baumann, C. A., Black, R. A., Baumann, G., and Frank, S. J. (2001) Phorbol ester-and growth factor-induced growth hormone (GH) receptor proteolysis and GH-binding protein shedding: relationship to GH receptor down-regulation Endocrinology 142, 1137-1147
27. Higashiyama, S. and Nanba, D. (2005) ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk Biochim. Biophys. Acta 1751, 110-117
28. Pandiella, A., Bosenberg, M. W., Huang, E. J., Besmer, P., and Massague, J. (1992) Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms J. Biol. Chem. 267, 24028-24033
29. Domula, M., Bykowska, K., Wegrzynowicz, Z., Lopaciuk, S., Weissbach, G., and Kopec, M. (1985) Plasma fibronectin concentrations in healthy and septic infants Eur. J. Pediatr. 144, 49-52
30. Legate, K. R., Wickstrom, S. A., and Fassler, R. (2009) Genetic and cell biological analysis of integrin outside-in signaling Genes Dev. 23, 397-418
31. Shen, C. X., Stewart, S., Wayner, E., Carter, W., and Wilkins, J. (1991) Antibodies to different members of the beta 1 (CD29) integrins induce homotypic and heterotypic cellular aggregation Cell Immunol. 138, 216-228
32. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res. 61, 4744-4749
33. Wilken, J. A. and Maihle, N. J. (2010) Primary trastuzumab resistance: new tricks for an old drug Ann. N.Y. Acad. Sci. 1210, 53-65
34. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massague, J. (1996) Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors J. Biol. Chem. 271, 11376-11382
35. Borroto, A., Ruiz-Paz, S., de la Torre, T. V., Borrell-Pages, M., Merlos-Suarez, A., Pandiella, A., Blobel, C. P., Baselga, J., and Arribas, J. (2003) Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding J. Biol. Chem. 278, 25933-25939
36. Dawson, J. P., Berger, M. B., Lin, C. C., Schlessinger, J., Lemmon, M. A., and Ferguson, K. M. (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface Mol. Cell. Biol. 25, 7734-7742
37. Wang, X. Q., Sun, P., and Paller, A. S. (2003) Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites J. Biol. Chem. 278, 48770-48778
38. Bill, H. M., Knudsen, B., Moores, S. L., Muthuswamy, S. K., Rao, V. R., Brugge, J. S., and Miranti, C. K. (2004) Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells Mol. Cell. Biol. 24, 8586-8599
39. Moro, L., Dolce, L., Cabodi, S., Bergatto, E., Boeri Erba, E., Smeriglio, M., Turco, E., Retta, S. F., Giuffrida, M. G., Venturino, M., Godovac-Zimmermann, J., Conti, A., Schaefer, E., Beguinot, L., Tacchetti, C., Gaggini, P., Silengo, L., Tarone, G., and Defilippi, P. (2002) Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines J. Biol. Chem. 277, 9405-9414
40. Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G., and Defilippi, P. (1998) Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival EMBO J. 17, 6622-6632
41. Kuwada, S. K. and Li, X. (2000) Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation Mol. Biol. Cell 11, 2485-2496
42. Marcoux, N. and Vuori, K. (2003) EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2 Oncogene 22, 6100-6106
43. Haley, J. D. and Gullick, W. J. (2008) EGFR Signaling Networks in Cancer Therapy (Haley, J. D. and Gullick, W. J., Eds.) Humana Press, New York.
44. Wilken, J. A., Baron, A. T., Foty, R. A., McCormick, D. J., and Maihle, N. J. (2011) Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and alpha5-integrin Biochemistry 50, 4309-4321
45. Ieguchi, K., Fujita, M., Ma, Z., Davari, P., Taniguchi, Y., Sekiguchi, K., Wang, B., Takada, Y. K., and Takada, Y. (2010) Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling J. Biol. Chem. 285, 31388-31398
46. Bax, D. V., Messent, A. J., Tart, J., van Hoang, M., Kott, J., Maciewicz, R. A., and Humphries, M. J. (2004) Integrin alpha5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells J. Biol. Chem. 279, 22377-22386
47. Brakebusch, C., Varfolomeev, E. E., Batkin, M., and Wallach, D. (1994) Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor J. Biol. Chem. 269, 32488-32496
48. Adamczyk, K. A., Klein-Scory, S., Tehrani, M. M., Warnken, U., Schmiegel, W., Schnolzer, M., and Schwarte-Waldhoff, I. (2011) Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells Life Sci. 89, 304-312
49. Filmus, J., Pollak, M. N., Cailleau, R., and Buick, R. N. (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF Biochem. Biophys. Res. Commun. 128, 898-905
50. Balmer, L. A., Beveridge, D. J., Jazayeri, J. A., Thomson, A. M., Walker, C. E., and Leedman, P. J. (2001) Identification of a novel AU-Rich element in the 3′ untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins Mol. Cell. Biol. 21, 2070-2084
51. Hinkle, C. L., Mohan, M. J., Lin, P., Yeung, N., Rasmussen, F., Milla, M. E., and Moss, M. L. (2003) Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha) Biochemistry 42, 2127-2136
52. Juanes, P. P., Ferreira, L., Montero, J. C., Arribas, J., and Pandiella, A. (2005) N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity Biochem. J. 389, 161-172
53. Nagano, O. and Saya, H. (2004) Mechanism and biological significance of CD44 cleavage Cancer Sci 95, 930-935
54. Craig, S. E. and Brady-Kalnay, S. M. (2011) Cancer cells cut homophilic cell adhesion molecules and run Cancer Res. 71, 303-309
55. Liao, H. J. and Carpenter, G. (2012) Regulated intramembrane cleavage of the EGF receptor Traffic 13, 1106-1112
56. Vazquez-Martin, A., Oliveras-Ferraros, C., Cufi, S., Del Barco, S., Martin-Castillo, B., and Menendez, J. A. (2011) Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth J. Cell Physiol. 226, 52-57
57. Baron, A. T., Lafky, J. M., Suman, V. J., Hillman, D. W., Buenafe, M. C., Boardman, C. H., Podratz, K. C., Perez, E. A., and Maihle, N. J. (2001) A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women Cancer Epidemiol. Biomarkers Prev. 10, 1175-1185
58. Leslie, K. K., Sill, M. W., Fischer, E., Darcy, K. M., Mannel, R. S., Tewari, K. S., Hanjani, P., Wilken, J. A., Baron, A. T., Godwin, A. K., Schilder, R. J., Singh, M., and Maihle, N. J. (2013) A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study Gynecol Oncol. 129, 486-494
59. Spindler, G. K., Olsen, D., Brandslunc, I., and Jakobsen, A. (2009) Treatment related changes of the serum epidermal growth factor receptor in advanced colorectal cancer J. Clin. Oncol. 27 e22096